Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 1, 2015, Pages 12-25

  Yun, Seongseok ^a   Vincelette, Nicole D ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Bone morphogenetic protein; Erythroferrone; Ferroportin; Hemochromatosis; Hepcidin; Iron metabolism

Indexed keywords

BONE MORPHOGENETIC PROTEIN; ERYTHROPOIETIN; FERROPORTIN; HEMOJUVELIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR; IRON; IRON CHELATING AGENT; IRON RESPONSE PROTEIN DERIVATIVE; JANUS KINASE; PROTEIN DERIVATIVE; SMAD PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; CATION TRANSPORT PROTEIN; METAL TRANSPORTING PROTEIN 1;

ANEMIA; CELL ACTIVITY; CELL LEVEL; CHRONIC DISEASE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE COURSE; ERYTHROPOIESIS; GENETIC DISORDER; HEMOCHROMATOSIS; HORMONE ACTION; HUMAN; HYPOXEMIA; INFLAMMATION; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; IRON RESPONSIVE ELEMENT; IRON STORAGE; IRON TRANSPORT; MOLECULAR PATHOLOGY; NONHUMAN; PHLEBOTOMY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CATION TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HEMOCHROMATOSIS; HEPCIDINS; HUMANS; IRON; MUTATION; SIGNAL TRANSDUCTION;

EID: 84930822337     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.02.006     Document Type: Review

References (133)

1. Andrews P.A. Disorders of iron metabolism. N Engl J Med 2000, 342(17):1293. (author reply 1294).
2. Ganz T. Hepcidin and iron regulation 10 years later. Blood 2011, 117(17):4425-4433.
3. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117(3):285-297.
4. Gomme P.T., McCann K.B., Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discovery Today 2005, 10(4):267-273.
5. Wally J., Halbrooks P.J., Vonrhein C., et al. The crystal structure of iron-free human serum transferrin provides insight into inter-lobe communication and receptor binding. J Biol Chem 2006, 281(34):24934-24944.
6. Cheng Y., Zak O., Aisen P., Harrison S.C., Walz T. Single particle reconstruction of the human apo-transferrin-transferrin receptor complex. J Struct Biol 2005, 152(3):204-210.
7. Cheng Y., Zak O., Aisen P., Harrison S.C., Walz T. Structure of the human transferrin receptor-transferrin complex. Cell 2004, 116(4):565-576.
8. Fleming M.D., Trenor C.C., Su M.A., et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997, 16(4):383-386.
9. Fleming M.D., Romano M.A., Su M.A., Garrick L.M., Garrick M.D., Andrews N.C. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron F transport. Proc Natl Acad Sci USA 1998, 95(3):1148-1153.
10. Kristiansen M., Graversen J.H., Jacobsen C., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409(6817):198-201.
11. McKie A.T., Barrow D., Latunde-Dada G.O., et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001, 291(5509):1755-1759.
12. Torti F.M., Torti S.V. Regulation of ferritin genes and protein. Blood 2002, 99(10):3505-3516.
13. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102(3):783-788.
14. Mastrogiannaki M., Matak P., Delga S., Deschemin J.C., Vaulont S., Peyssonnaux C. Deletion of HIF-2α in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice. Blood 2012, 119(2):587-590.
15. Mastrogiannaki M., Matak P., Mathieu J.R., et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica 2012, 97(6):827-834.
16. Mastrogiannaki M., Matak P., Keith B., Simon M.C., Vaulont S., Peyssonnaux C. HIF-2 alpha, but not HIF-1 alpha, promotes iron absorption in mice. J Clin Invest 2009, 119(5):1159-1166.
17. Pak M., Lopez M.A., Gabayan V., Ganz T., Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006, 108(12):3730-3735.
18. Pasricha S.R., Frazer D.M., Bowden D.K., Anderson G.J. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood 2013, 122(1):124-133.
19. Liu Q., Davidoff O., Niss K., Haase V.H. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 2012, 122(12):4635-4644.
20. Steinbicker A.U., Bartnikas T.B., Lohmeyer L.K., et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood 2011, 118(15):4224-4230.
21. Mayeur C., Lohmeyer L.K., Leyton P., et al. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6. Blood 2014, 123(14):2261-2268.
22. Lin L., Valore E.V., Nemeth E., Goodnough J.B., Gabayan V., Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007, 110(6):2182-2189.
23. Steinbicker A.U., Sachidanandan C., Vonner A.J., et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 2011, 117(18):4915-4923.
24. Pigeon C., Ilyin G., Courselaud B., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001, 276(11):7811-7819.
25. Frazer D.M., Wilkins S.J., Becker E.M., et al. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 2002, 123(3):835-844.
26. Nicolas G., Bennoun M., Devaux I., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001, 98(15):8780-8785.
27. Nicolas G., Bennoun M., Porteu A., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002, 99(7):4596-4601.
28. Meynard D., Kautz L., Darnaud V., Canonne-Hergaux F., Coppin H., Roth M.P. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009, 41(4):478-481.
29. Andriopoulos B., Corradini E., Xia Y., et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009, 41(4):482-487.
30. Babitt J.L., Huang F.W., Wrighting D.M., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38(5):531-539.
31. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
32. Qiao B., Sugianto P., Fung E., et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab 2012, 15(6):918-924.
33. Babitt J.L., Huang F.W., Xia Y., Sidis Y., Andrews N.C., Lin H.Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007, 117(7):1933-1939.
34. Wang R.H., Li C., Xu X., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005, 2(6):399-409.
35. Niederkofler V., Salie R., Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005, 115(8):2180-2186.
36. Roetto A., Totaro A., Cazzola M., et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999, 64(5):1388-1393.
37. Gao J., Chen J., Kramer M., Tsukamoto H., Zhang A.S., Enns C.A. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009, 9(3):217-227.
38. Bridle K.R., Frazer D.M., Wilkins S.J., et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003, 361(9358):669-673.
39. Zoller H., Pietrangelo A., Vogel W., Weiss G. Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet 1999, 353(9170):2120-2123.
40. Nicolas G., Viatte L., Lou D.Q., et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003, 34(1):97-101.
41. Muckenthaler M., Roy C.N., Custodio A.O., et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet 2003, 34(1):102-107.
42. Ahmad K.A., Ahmann J.R., Migas M.C., et al. Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells Mol Dis 2002, 29(3):361-366.
43. Kautz L., Meynard D., Besson-Fournier C., et al. BMP/Smad signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression. Blood 2009, 114(12):2515-2520.
44. Kawabata H., Fleming R.E., Gui D., et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2005, 105(1):376-381.
45. Kautz L., Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. Blood 2014, 124(4):479-482.
46. Kapitsinou P.P., Liu Q., Unger T.L., et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 2010, 116(16):3039-3048.
47. Haase V.H. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 2013, 27(1):41-53.
48. Nicolas G., Chauvet C., Viatte L., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110(7):1037-1044.
49. Gardenghi S., Marongiu M.F., Ramos P., et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007, 109(11):5027-5035.
50. Origa R., Galanello R., Ganz T., et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007, 92(5):583-588.
51. Jenkins Z.A., Hagar W., Bowlus C.L., et al. Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol 2007, 24(4):237-243.
52. Kattamis A., Papassotiriou I., Palaiologou D., et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006, 91(6):809-812.
53. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007, 13(9):1096-1101.
54. Tanno T., Porayette P., Sripichai O., et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009, 114(1):181-186.
55. Waalen J., von Löhneysen K., Lee P., Xu X., Friedman J.S. Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol 2011, 87(2):107-116.
56. Casanovas G., Vujić Spasic M., Casu C., et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2013, 98(3):444-447.
57. Kautz L., Jung G., Valore E.V., Rivella S., Nemeth E., Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014, 46(7):678-684.
58. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352(10):1011-1023.
59. Yang F., Liu X.B., Quinones M., Melby P.C., Ghio A., Haile D.J. Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J Biol Chem 2002, 277(42):39786-39791.
60. Ludwiczek S., Aigner E., Theurl I., Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003, 101(10):4148-4154.
61. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101(7):2461-2463.
62. Pietrangelo A., Dierssen U., Valli L., et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007, 132(1):294-300.
63. Sakamori R., Takehara T., Tatsumi T., et al. STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo. J Gastroenterol 2010, 45(2):244-248.
64. Wrighting D.M., Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108(9):3204-3209.
65. Verga Falzacappa M.V., Vujic Spasic M., Kessler R., Stolte J., Hentze M.W., Muckenthaler M.U. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007, 109(1):353-358.
66. Theurl I., Schroll A., Sonnweber T., et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011, 118(18):4977-4984.
67. Mignone F., Gissi C., Liuni S., Pesole G. Untranslated regions of mRNAs. Genome Biol 2002, 3(3). (REVIEWS0004).
68. Glisovic T., Bachorik J.L., Yong J., Dreyfuss G. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett 2008, 582(14):1977-1986.
69. Hentze M.W., Kühn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 1996, 93(16):8175-8182.
70. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004, 350(23):2383-2397.
71. Pietrangelo A., Montosi G., Totaro A., et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999, 341(10):725-732.
72. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13(4):399-408.
73. Olynyk J.K., Cullen D.J., Aquilia S., Rossi E., Summerville L., Powell L.W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999, 341(10):718-724.
74. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005, 352(17):1769-1778.
75. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002, 359(9302):211-218.
76. Allen K.J., Gurrin L.C., Constantine C.C., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008, 358(3):221-230.
77. Asberg A., Hveem K., Thorstensen K., et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001, 36(10):1108-1115.
78. Lebrón J.A., Bennett M.J., Vaughn D.E., et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998, 93(1):111-123.
79. Gross C.N., Irrinki A., Feder J.N., Enns C.A. Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation. J Biol Chem 1998, 273(34):22068-22074.
80. Feder J.N., Penny D.M., Irrinki A., et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998, 95(4):1472-1477.
81. Roy C.N., Penny D.M., Feder J.N., Enns C.A. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem 1999, 274(13):9022-9028.
82. Waheed A., Grubb J.H., Zhou X.Y., et al. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 2002, 99(5):3117-3122.
83. Waheed A., Parkkila S., Zhou X.Y., et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 1997, 94(23):12384-12389.
84. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004, 36(1):77-82.
85. Roetto A., Papanikolaou G., Politou M., et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003, 33(1):21-22.
86. Camaschella C. BMP6 orchestrates iron metabolism. Nat Genet 2009, 41(4):386-388.
87. Fleming R.E., Ahmann J.R., Migas M.C., et al. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci USA 2002, 99(16):10653-10658.
88. Girelli D., Bozzini C., Roetto A., et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002, 122(5):1295-1302.
89. Hofmann W.K., Tong X.J., Ajioka R.S., Kushner J.P., Koeffler H.P. Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis. Blood 2002, 100(3):1099-1100.
90. Hattori A., Wakusawa S., Hayashi H., et al. AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol Res 2003, 26(2):154-156.
91. Montosi G., Donovan A., Totaro A., et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001, 108(4):619-623.
92. Njajou O.T., Vaessen N., Joosse M., et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001, 28(3):213-214.
93. McKie A.T., Marciani P., Rolfs A., et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000, 5(2):299-309.
94. Zaahl M.G., Merryweather-Clarke A.T., Kotze M.J., van der Merwe S., Warnich L., Robson K.J. Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet 2004, 115(5):409-417.
95. Cremonesi L., Cemonesi L., Forni G.L., et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol 2005, 131(5):663-670.
96. Gordeuk V.R., Caleffi A., Corradini E., et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003, 31(3):299-304.
97. Nekhai S., Xu M., Foster A., et al. Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. Haematologica 2013, 98(3):455-463.
98. Del-Castillo-Rueda A., Moreno-Carralero M.I., Alvarez-Sala-Walther L.A., et al. Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish man. Eur J Haematol 2011, 86(3):260-264.
99. Gattermann N. The treatment of secondary hemochromatosis. Dtsch Arztebl Int 2009, 106(30):499-504. I.
100. Edwards C.Q., Cartwright G.E., Skolnick M.H., Amos D.B. Homozygosity for hemochromatosis: clinical manifestations. Ann Intern Med 1980, 93(4):519-525.
101. Milder M.S., Cook J.D., Stray S., Finch C.A. Idiopathic hemochromatosis, an interim report. Medicine (Baltimore) 1980, 59(1):34-49.
102. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985, 313(20):1256-1262.
103. Adams P.C., Kertesz A.E., Valberg L.S. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991, 90(4):445-449.
104. Bacon B.R., Sadiq S.A. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997, 92(5):784-789.
105. Bacon B.R., Tavill A.S., Brittenham G.M., Park C.H., Recknagel R.O. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest 1983, 71(3):429-439.
106. Bacon B.R., Park C.H., Brittenham G.M., O'Neill R., Tavill A.S. Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload. Hepatology 1985, 5(5):789-797.
107. Olynyk J.K., Britton R.S., Stephenson A.H., Leicester K.L., O'Neill R., Bacon B.R. An in vitro model for the study of phagocytosis of damaged hepatocytes by rat Kupffer cells. Liver 1999, 19(5):418-422.
108. Gurrin L.C., Osborne N.J., Constantine C.C., et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 2008, 135(6):1945-1952.
109. Bacon B.R., Adams P.C., Kowdley K.V., Powell L.W., Tavill A.S., Diseases AAftSoL. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(1):328-343.
110. Tavill A.S., Diseases AAftSoL, Gastroenterology ACo, Association A.G. Diagnosis and management of hemochromatosis. Hepatology 2001, 33(5):1321-1328.
111. Bassett M.L., Halliday J.W., Ferris R.A., Powell L.W. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology 1984, 87(3):628-633.
112. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007, 46(4):1291-1301.
113. Adams P.C., Speechley M., Kertesz A.E. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991, 101(2):368-372.
114. Niederau C., Fischer R., Pürschel A., Stremmel W., Häussinger D., Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996, 110(4):1107-1119.
115. Adams P.C., Barton J.C. How I treat hemochromatosis. Blood 2010, 116(3):317-325.
116. Falize L., Guillygomarc'h A., Perrin M., et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006, 44(2):472-477.
117. Elmberg M., Hultcrantz R., Ekbom A., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003, 125(6):1733-1741.
118. Osborne N.J., Gurrin L.C., Allen K.J., et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010, 51(4):1311-1318.
119. Lynch S.R., Skikne B.S., Cook J.D. Food iron absorption in idiopathic hemochromatosis. Blood 1989, 74(6):2187-2193.
120. Barton J.C., Bottomley S.S. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis. Am J Hematol 2000, 65(3):223-226.
121. Mariani R., Pelucchi S., Perseghin P., Corengia C., Piperno A. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005, 90(5):717-718.
122. Rombout-Sestrienkova E., van Noord P.A., van Deursen C.T., Sybesma B.J., Nillesen-Meertens A.E., Koek G.H. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis-a pilot study. Transfus Apher Sci 2007, 36(3):261-267.
123. Piga A., Gaglioti C., Fogliacco E., Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003, 88(5):489-496.
124. Galanello R., Kattamis A., Piga A., et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006, 91(9):1241-1243.
125. Cohen A.R., Galanello R., Piga A., De Sanctis V., Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003, 102(5):1583-1587.
126. Cohen A.R., Galanello R., Piga A., Dipalma A., Vullo C., Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000, 108(2):305-312.
127. Nielsen P., Fischer R., Buggisch P., Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 2003, 123(5):952-953.
128. Cappellini M.D., Cohen A., Piga A., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006, 107(9):3455-3462.
129. Phatak P., Brissot P., Wurster M., et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010, 52(5):1671-1779.
130. Yamasaki T., Terai S., Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011, 365(6):576-578.
131. Sakaida I., Hironaka K., Uchida K., Okita K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient l-amino acid-defined diet in rats. Dig Dis Sci 1999, 44(3):560-569.
132. Hutchinson C., Geissler C.A., Powell J.J., Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007, 56(9):1291-1295.
133. Gunshin H., Mackenzie B., Berger U.V., et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997, 388(6641):482-488.